You are here

A Trial To Assess The Safety, Tolerability, Pharmacokinetics, And Pharmacodynamics Of Single Doses Of PF-04937319 In Subjects With Type 2 Diabetes Mellitus

Last updated on March 14, 2019

FOR MORE INFORMATION
Study Location
Dedicated Phase 1
Phoenix, Arizona, 85013 United States
Contact
1-800-718-1021
Eligibility criteria
Condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Type 2 Diabetes Mellitus
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
18-65 years
Inclusion criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

- Patients with type 2 diabetes mellitus who are taking stable doses of metformin only.
Subjects treated with a sulfonylurea (SU) or a dipeptidyl peptidase-IV inhibitor
(DPP-IVi) in combination with metformin may be eligible if washed off the SU or
DPP-IVi to metformin only for a minimum of 4 weeks before dosing.

- Male and/or female subjects (females will be women of non childbearing potential)
between the ages of 18 and 65 years, inclusive, with a body mass index (BMI) of 18.5
to 45.0 kg/m2 and C-peptide >0.8 ng/mL.

- Screening and Day -2 troponin I concentration =0.05 ng/mL as measured by the Bayer
Centaur Ultra assay.

- HbA1c >/=7% and =11%. If the patient requires to be washed off an SU or DPP-IVi, the
HbA1c limits will be >/=7% and =9.5%.

Exclusion criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details

- Evidence or history of clinically significant hematological, renal, endocrine,
pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic, or
allergic disease (including drug allergies, but excluding untreated, asymptomatic,
seasonal allergies at time of dosing).

- Evidence or history of diabetic complications with significant end organ damage, eg,
proliferative retinopathy and/or macular edema, creatinine clearance =60 mL/min
based on the Cockcroft-Gault equation, diabetic neuropathy complicated by neuropathic
ulcers.

- History of stroke, transient ischemic attack, or myocardial infarction within the past
6 months. Additionally, history of coronary artery bypass graft or stent implantation,
clinically significant peripheral vascular disease, or congestive heart failure (NYHA
Classes II-IV). Furthermore, a current history of angina/unstable angina. Also, 12
lead electrocardiogram (ECG) demonstrating QTc >450 msec at screening, ECG findings
suggestive of asymptomatic myocardial ischemia, or supine blood pressure >/=160 mm Hg
(systolic) or =100 mm Hg (diastolic).

- One or more self reported episodes of hypoglycemia within the last 3 months, or two or
more self reported episodes of hypoglycemia within the last 6 months.

- Screening or Day -2 fasting (>/=8 hours) blood glucose, =70 or >/=270 mg/dL,
confirmed by a single repeat if deemed necessary.

NCT01044537
Pfizer
Completed
A Trial To Assess The Safety, Tolerability, Pharmacokinetics, And Pharmacodynamics Of Single Doses Of PF-04937319 In Subjects With Type 2 Diabetes Mellitus

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

call now

Try a new search

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.

Based on your search, you may also be interested in

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting the study website. Please see the references below:

BY PHONE

Pfizer Clinical Trials Contact Center

1-800-718-1021

BY EMAIL

Contact

[email protected]

Call Now